KR102805002B1 - Pd-l1 발현의 감소를 위한 올리고뉴클레오티드 - Google Patents

Pd-l1 발현의 감소를 위한 올리고뉴클레오티드 Download PDF

Info

Publication number
KR102805002B1
KR102805002B1 KR1020237031671A KR20237031671A KR102805002B1 KR 102805002 B1 KR102805002 B1 KR 102805002B1 KR 1020237031671 A KR1020237031671 A KR 1020237031671A KR 20237031671 A KR20237031671 A KR 20237031671A KR 102805002 B1 KR102805002 B1 KR 102805002B1
Authority
KR
South Korea
Prior art keywords
oligonucleotide
nucleosides
delete delete
region
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237031671A
Other languages
English (en)
Korean (ko)
Other versions
KR20230136689A (ko
Inventor
뤼케 페데르센
하싼 자반바크트
말레네 야케로트
쇠렌 오토센
수팔론 루앙세
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Priority to KR1020257014623A priority Critical patent/KR20250065735A/ko
Publication of KR20230136689A publication Critical patent/KR20230136689A/ko
Application granted granted Critical
Publication of KR102805002B1 publication Critical patent/KR102805002B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
KR1020237031671A 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드 Active KR102805002B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257014623A KR20250065735A (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16160149.7 2016-03-14
EP16160149 2016-03-14
KR1020227022628A KR102580776B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
PCT/EP2017/055925 WO2017157899A1 (en) 2016-03-14 2017-03-14 Oligonucleotides for reduction of pd-l1 expression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022628A Division KR102580776B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014623A Division KR20250065735A (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드

Publications (2)

Publication Number Publication Date
KR20230136689A KR20230136689A (ko) 2023-09-26
KR102805002B1 true KR102805002B1 (ko) 2025-05-09

Family

ID=58314191

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020187026546A Active KR102306797B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
KR1020227022628A Active KR102580776B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
KR1020257014623A Pending KR20250065735A (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
KR1020217030513A Active KR102417646B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
KR1020237031671A Active KR102805002B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드

Family Applications Before (4)

Application Number Title Priority Date Filing Date
KR1020187026546A Active KR102306797B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
KR1020227022628A Active KR102580776B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
KR1020257014623A Pending KR20250065735A (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
KR1020217030513A Active KR102417646B1 (ko) 2016-03-14 2017-03-14 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드

Country Status (30)

Country Link
US (5) US20170283496A1 (enExample)
EP (2) EP3430141B1 (enExample)
JP (3) JP6748219B2 (enExample)
KR (5) KR102306797B1 (enExample)
CN (5) CN114085836B (enExample)
AR (2) AR108038A1 (enExample)
AU (4) AU2017235278C1 (enExample)
CA (2) CA3120687A1 (enExample)
CL (4) CL2018002570A1 (enExample)
CO (1) CO2018007761A2 (enExample)
CR (2) CR20180432A (enExample)
DK (1) DK3430141T3 (enExample)
ES (1) ES2857702T3 (enExample)
HR (1) HRP20210315T1 (enExample)
HU (1) HUE053172T2 (enExample)
IL (5) IL317818A (enExample)
LT (1) LT3430141T (enExample)
MX (2) MX2018010830A (enExample)
MY (1) MY194912A (enExample)
PE (3) PE20201499A1 (enExample)
PH (1) PH12018501964A1 (enExample)
PL (1) PL3430141T3 (enExample)
PT (1) PT3430141T (enExample)
RS (1) RS61528B1 (enExample)
RU (1) RU2747822C2 (enExample)
SG (1) SG11201807854SA (enExample)
SI (1) SI3430141T1 (enExample)
TW (5) TW202428874A (enExample)
UA (1) UA127432C2 (enExample)
WO (1) WO2017157899A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
KR20180033537A (ko) 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도
HRP20210315T1 (hr) * 2016-03-14 2021-04-16 F. Hoffmann - La Roche Ag Oligonukleotidi za smanjenje ekspresije pd-l1
CN109477103A (zh) 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ 单链rna-编辑寡核苷酸
WO2018024849A1 (en) * 2016-08-03 2018-02-08 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
ES2837076T3 (es) 2016-09-01 2021-06-29 Proqr Therapeutics Ii Bv Oligonucleótidos para la edición de ARN de cadena sencilla modificados químicamente
JP7288854B2 (ja) 2016-10-07 2023-06-08 セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー がんを治療するための新規アプローチ
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
PE20200868A1 (es) * 2017-10-16 2020-08-31 Hoffmann La Roche OLIGONUCLEOTIDOS ANTISENTIDO Y CONJUGADOS QUE LOS COMPRENDEN PARA LA REDUCCION DEL ARNm DE PAPD5 Y PAPD7
SG11202006528XA (en) * 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2019291050A1 (en) 2018-06-22 2020-12-24 F. Hoffmann-La Roche Ag Oligonucleotides for modulating SCN9A expression
WO2020007772A1 (en) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
WO2020011653A1 (en) * 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
CR20210015A (es) 2018-07-13 2021-03-22 Hoffmann La Roche Oligonucleótidos para modular la expresión de rtel 1
WO2020081585A1 (en) * 2018-10-15 2020-04-23 The Brigham And Women's Hospital, Inc. The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy
EP3934695A1 (en) * 2019-03-05 2022-01-12 F. Hoffmann-La Roche AG Intracellular targeting of molecules
WO2020201144A1 (en) 2019-04-02 2020-10-08 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for immunotherapy
CN114127286A (zh) * 2019-04-26 2022-03-01 斯托克制药公司 用于调节选择性内含子的剪接的方法和组合物
AU2020269886A1 (en) * 2019-05-03 2021-12-02 Secarna Pharmaceuticals Gmbh & Co. Kg PD-L1 antisense oligonucleotides for use in tumor treatment
JP2023506550A (ja) * 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
JP7634542B2 (ja) * 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
EP4077672A1 (en) * 2019-12-20 2022-10-26 F. Hoffmann-La Roche AG Enhanced oligonucleotides for inhibiting scn9a expression
AU2020415322A1 (en) * 2019-12-24 2022-06-16 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
WO2021173812A1 (en) * 2020-02-28 2021-09-02 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
WO2022029209A1 (en) 2020-08-05 2022-02-10 F. Hoffmann-La Roche Ag Oligonucleotide treatment of hepatitis b patients
CN114507663A (zh) * 2020-11-16 2022-05-17 浙江柏拉阿图医药科技有限公司 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
CN115216474B (zh) * 2021-04-15 2025-09-30 武汉大学 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用
US20240392289A1 (en) * 2021-08-04 2024-11-28 Hepagene Therapeutics (HK) Limited Ligand conjugates for delivery of therapeutically active agents
CN113789324B (zh) * 2021-08-17 2023-08-25 广东省大湾区华南理工大学聚集诱导发光高等研究院 一种aie探针及其制备方法与在荧光定量pcr方法中的应用
WO2023083906A2 (en) 2021-11-11 2023-05-19 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
CA3257440A1 (en) * 2022-07-06 2024-01-11 Adverum Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACHROMOTOPSY
TW202504619A (zh) * 2023-07-20 2025-02-01 大陸商上海舶望製藥有限公司 用於抑制pd-l1表達的組合物和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042237A2 (en) 2004-10-06 2006-04-20 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2011127180A1 (en) 2010-04-06 2011-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
RU2123528C1 (ru) * 1990-11-08 1998-12-20 Чирон Корпорейшн Способ получения белков hcv, пригодных для использования в вакцине или иммуноанализе, асиалогликопротеин (варианты), композиция для использования в вакцине или в иммуноанализе (варианты), способ очистки асиалогликопротеина и способ понижения содержания или элиминации hcv
ATE198598T1 (de) 1990-11-08 2001-01-15 Hybridon Inc Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden
AU2916292A (en) 1991-10-24 1993-05-21 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
DE69527857T2 (de) 1994-10-06 2003-05-28 Buchardt, Dorte Peptid-nukleinsäure-konjugate
US5684142A (en) 1995-06-07 1997-11-04 Oncor, Inc. Modified nucleotides for nucleic acid labeling
JP2000501414A (ja) 1995-11-22 2000-02-08 ザ・ジョンズ・ホプキンス・ユニバーシティー 生体分子の細胞取り込みを高めるリガンド
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6096875A (en) 1998-05-29 2000-08-01 The Perlein-Elmer Corporation Nucleotide compounds including a rigid linker
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6335432B1 (en) 1998-08-07 2002-01-01 Bio-Red Laboratories, Inc. Structural analogs of amine bases and nucleosides
US6335437B1 (en) 1998-09-07 2002-01-01 Isis Pharmaceuticals, Inc. Methods for the preparation of conjugated oligomers
RU2233844C2 (ru) 1999-02-12 2004-08-10 Санкио Компани Лимитед Новые нуклеозидные и олигонуклеотидные аналоги
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US20060276422A1 (en) 2001-05-18 2006-12-07 Nassim Usman RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA)
WO2005007855A2 (en) 2003-07-14 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1537878B1 (en) * 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
HUE042261T2 (hu) 2003-06-12 2019-06-28 Alnylam Pharmaceuticals Inc Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák
ATE387217T1 (de) 2003-07-11 2008-03-15 Lbr Medbiotech B V Mannose-6-phosphat rezeptor vermittelter gentransfer zu muskelzellen
ZA200703482B (en) * 2004-10-06 2008-09-25 Mayo Foundation B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007131237A2 (en) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
WO2009124238A1 (en) 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
US8575123B2 (en) 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
TWI729512B (zh) * 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2010101249A1 (ja) 2009-03-06 2010-09-10 国立大学法人三重大学 Ｔ細胞の機能増強方法
EP2427553A4 (en) * 2009-05-06 2012-11-07 Opko Curna Llc TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT
CA2764683A1 (en) * 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2571989A4 (en) * 2010-05-18 2014-08-13 Univ Mcgill METHOD FOR REDUCING THE EXPRESSION OF SPICY GLIOMES FROM DOWN REGULATED KIDNEY CELL CARCINOMES
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
KR101903778B1 (ko) 2010-10-28 2018-10-04 베니텍 바이오파마 리미티드 Hbv 치료
JP2014504295A (ja) 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
CN103282503B (zh) 2010-12-29 2015-12-02 弗·哈夫曼-拉罗切有限公司 用于细胞内递送核酸的小分子缀合物
MX340408B (es) 2011-04-21 2016-07-07 Ionis Pharmaceuticals Inc Modulacion de la expresion del virus de hepatitis b (vhb).
TW202244278A (zh) 2011-06-30 2022-11-16 美商艾羅海德製藥公司 用於抑制ｂ型肝炎病毒基因表現之組合物及方法
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
EP2751270B1 (en) 2011-08-29 2018-08-22 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
CN104136451A (zh) 2011-09-07 2014-11-05 玛瑞纳生物技术有限公司 具有构象限制的单体的核酸化合物的合成和用途
WO2013049307A2 (en) 2011-09-30 2013-04-04 University Of Miami Enhanced immune memory development by aptamer targeted mtor inhibition of t cells
LT2768524T (lt) * 2011-10-17 2022-07-25 Io Biotech Aps Pd-l1 grindžiama imunoterapija
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
EA201492120A1 (ru) * 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии atp2a2
JP2016528873A (ja) 2012-05-16 2016-09-23 ラナ セラピューティクス インコーポレイテッド 遺伝子発現を調節するための組成物及び方法
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
MX2015009056A (es) * 2013-01-30 2015-10-05 Hoffmann La Roche Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos.
BR112015027322A8 (pt) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Compostos antissenso conjugados e sua utilização
MX391977B (es) 2013-06-27 2025-03-21 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9).
EP3102697A1 (en) * 2014-02-03 2016-12-14 Myriad Genetics, Inc. Method for predicting the response to an anti-her2 containing therapy and/or chemotherapy in patients with breast cancer
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
CN106795200B (zh) 2014-10-10 2020-06-19 豪夫迈·罗氏有限公司 Galnac亚磷酰胺、其核酸缀合物及其用途
US9828601B2 (en) 2015-02-27 2017-11-28 Idera Pharmaceuticals, Inc. Compositions for inhibiting checkpoint gene expression and uses thereof
GB201507926D0 (en) * 2015-05-08 2015-06-24 Proqr Therapeutics N V Improved treatments using oligonucleotides
KR20180073584A (ko) * 2015-10-02 2018-07-02 로슈 이노베이션 센터 코펜하겐 에이/에스 올리고뉴클레오타이드 접합 방법
MX378999B (es) 2015-11-16 2025-03-10 Hoffmann La Roche Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).
EP3387131A4 (en) 2015-12-09 2019-08-07 Alnylam Pharmaceuticals, Inc. POLYNUCLEOTIDE AGENTS TARGETING LIGAND 1 OF PROGRAMMED CELL DEATH 1 (PD-L1) AND THEIR METHODS OF USE
HRP20210315T1 (hr) 2016-03-14 2021-04-16 F. Hoffmann - La Roche Ag Oligonukleotidi za smanjenje ekspresije pd-l1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042237A2 (en) 2004-10-06 2006-04-20 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2011127180A1 (en) 2010-04-06 2011-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates

Also Published As

Publication number Publication date
CL2020000865A1 (es) 2020-08-28
TWI721128B (zh) 2021-03-11
PE20181892A1 (es) 2018-12-11
EP3786297A1 (en) 2021-03-03
PL3430141T3 (pl) 2022-02-28
RU2747822C2 (ru) 2021-05-14
AU2017235278A1 (en) 2018-08-09
TW202428874A (zh) 2024-07-16
AU2017235278A8 (en) 2018-08-16
JP2019512498A (ja) 2019-05-16
AU2021236439B2 (en) 2022-06-16
TW201734209A (zh) 2017-10-01
US20170283496A1 (en) 2017-10-05
PE20230157A1 (es) 2023-02-01
IL303077A (en) 2023-07-01
IL317818A (en) 2025-02-01
JP6748219B2 (ja) 2020-08-26
PT3430141T (pt) 2021-02-25
UA127432C2 (uk) 2023-08-23
JP2024029180A (ja) 2024-03-05
TWI790485B (zh) 2023-01-21
DK3430141T3 (da) 2021-03-01
RS61528B1 (sr) 2021-04-29
KR102580776B1 (ko) 2023-09-20
AU2017235278B2 (en) 2021-11-11
TW202328448A (zh) 2023-07-16
EP3430141A1 (en) 2019-01-23
KR20230136689A (ko) 2023-09-26
CN114717235A (zh) 2022-07-08
TW202128997A (zh) 2021-08-01
LT3430141T (lt) 2021-03-25
KR20220100095A (ko) 2022-07-14
US20230331837A1 (en) 2023-10-19
CN114736900A (zh) 2022-07-12
CO2018007761A2 (es) 2018-08-10
RU2018134379A3 (enExample) 2020-06-23
IL303077B1 (en) 2025-02-01
JP7447073B2 (ja) 2024-03-11
KR102306797B1 (ko) 2021-10-05
HRP20210315T1 (hr) 2021-04-16
SI3430141T1 (sl) 2021-04-30
AU2022202479B2 (en) 2025-03-20
AU2017235278C1 (en) 2022-03-10
CA3013683C (en) 2021-07-13
CN114736900B (zh) 2024-05-10
AU2024203581A1 (en) 2024-06-20
CN114085836A (zh) 2022-02-25
MX2022012221A (es) 2022-10-27
PH12018501964A1 (en) 2019-06-24
IL290294B2 (en) 2023-02-01
US20200247884A1 (en) 2020-08-06
US20210147535A1 (en) 2021-05-20
US20200048344A1 (en) 2020-02-13
IL296483B1 (en) 2023-06-01
TWI840950B (zh) 2024-05-01
CR20180432A (es) 2018-11-21
KR102417646B1 (ko) 2022-07-07
US10745480B2 (en) 2020-08-18
CN114085836B (zh) 2024-01-26
US10829555B2 (en) 2020-11-10
SG11201807854SA (en) 2018-10-30
ES2857702T3 (es) 2021-09-29
MX2018010830A (es) 2019-02-07
EP3430141B1 (en) 2020-12-30
IL303077B2 (en) 2025-06-01
JP2020172488A (ja) 2020-10-22
CN114736901B (zh) 2024-05-31
CL2018002570A1 (es) 2018-12-28
IL296483A (en) 2022-11-01
BR112018068410A2 (pt) 2019-01-15
CL2020001127A1 (es) 2020-08-28
PE20201499A1 (es) 2020-12-29
AU2022202479A1 (en) 2022-05-12
IL260759B (en) 2022-03-01
CA3013683A1 (en) 2017-09-21
AR108038A1 (es) 2018-07-11
AU2021236439A1 (en) 2021-10-14
IL290294A (en) 2022-04-01
CN108779465A (zh) 2018-11-09
US11466081B2 (en) 2022-10-11
IL290294B (en) 2022-10-01
CN114736901A (zh) 2022-07-12
CL2020001126A1 (es) 2020-08-28
KR20250065735A (ko) 2025-05-13
TW202128998A (zh) 2021-08-01
WO2017157899A1 (en) 2017-09-21
HUE053172T2 (hu) 2021-06-28
AR118719A2 (es) 2021-10-27
CA3120687A1 (en) 2017-09-21
KR20210120131A (ko) 2021-10-06
JP7002603B2 (ja) 2022-02-10
CN108779465B (zh) 2022-05-13
IL296483B2 (en) 2023-10-01
JP2022034059A (ja) 2022-03-02
TWI794662B (zh) 2023-03-01
MY194912A (en) 2022-12-22
CR20200119A (es) 2021-04-19
NZ744548A (en) 2024-05-31
KR20180120702A (ko) 2018-11-06
RU2018134379A (ru) 2020-04-15

Similar Documents

Publication Publication Date Title
KR102805002B1 (ko) Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
RU2835926C1 (ru) Олигонуклеотиды для понижения экспрессии pd-l1
HK40077417A (en) Oligonucleotides for reduction of pd-l1 expression
HK40077445A (en) Oligonucleotides for reduction of pd-l1 expression
HK40077444A (en) Oligonucleotides for reduction of pd-l1 expression
HK40064608A (en) Oligonucleotides for reduction of pd-l1 expression
HK40077445B (zh) 用於减少pd-l1表达的寡核苷酸
HK40077417B (zh) 用於减少pd-l1表达的寡核苷酸
HK40064608B (zh) 用於减少pd-l1表达的寡核苷酸
JP7791222B2 (ja) Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230915

Application number text: 1020227022628

Filing date: 20220701

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240102

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0701 Decision of registration after re-examination

Patent event date: 20250205

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
PG1601 Publication of registration